Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.
US-based pharmaceutical company Moderna has been collaborating with the Vaccine Innovation Center of Korea University College of Medicine on an mRNA vaccine targeting hantavirus since 2023. The project gained attention after an outbreak struck the MV Hondius, a Dutch vessel that sailed from Argentina and reached the Canary Islands on May 10. At least three passengers died and several others suffered serious illness during the incident.
